Namely, the therapeutic effect in PCa is mainly due to PSMA overexpression in PCa cell membranes, whereas in other cancers, the prevalent expression by the tumour-associated endothelium may limit the efficacy of radioligand treatment. The gene discussed is FOLH1; the disease is posterior cortical atrophy.